Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model.
Mohammed H UddinMohammad Najeeb Al-HallakHusain Yar KhanAmro AboukameelYiwei LiSahar F BannouraGregory DysonSeongho KimYosef MzannarIbrahim AzarTanya OdishoAmr MohamedYosef LandesmanSteve KimRafic BeydounRamzi M MohammadPhilip A PhilipAnthony F ShieldsAsfar S AzmiPublished in: Clinical and translational medicine (2023)
The majority of pancreatic ductal adenocarcinoma (PDAC) patients experience disease progression while on treatment with gemcitabine and nanoparticle albumin-bound (nab)-paclitaxel (GemPac). Exporter protein exportin 1 (XPO1) inhibitor selinexor (Sel) with GemPac synergistically inhibited the growth of LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx1-Cre (KPC) mouse derived cell line and enhanced the survival of mice. Digital spatial profiling shows that Sel-GemPac causes broad perturbation of PDAC-supporting signalling in the KPC model.
Keyphrases
- klebsiella pneumoniae
- mouse model
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- advanced non small cell lung cancer
- escherichia coli
- prognostic factors
- multidrug resistant
- type diabetes
- single cell
- metabolic syndrome
- patient reported outcomes
- high fat diet induced
- epidermal growth factor receptor
- wild type